Abstracts tagged "pulmonary"

Abstract Number: 1049 • ACR Convergence 2022
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Hilde Jenssen Bjørkekjær¹, cosimo bruni², PATRICIA E CARREIRA³, Paolo Airò⁴, CARMEN PILAR SIMEON⁵, Marie-Elise Truchetet⁶, Alessandro Giollo⁷, Alexandra Balbir-Gurman⁸, Mickaël MARTIN⁹, Chris Denton¹⁰, Armando Gabrielli¹¹, Håvard Fretheim¹², Imon Barua¹², Helle Bitter¹³, Øyvind Midtvedt¹², Kaspar Broch¹⁴, Arne Andreassen¹², Yoshiya Tanaka¹⁵, Gabriela Riemekasten¹⁶, Ulf Müller-Ladner¹⁷, Marco Matucci-Cerinic², Ivan Castellvi¹⁸, Elise Siegert¹⁹, Eric Hachulla²⁰, Oliver Distler²¹ and Anna-Maria Hoffmann-Vold¹², ¹Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, ²University of Florence, Florence, Italy, ³HOSPITAL 12 DE OCTUBRE, Madrid, Spain, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, ⁵Hospital Vall D'Hebron, Barcelona, Spain, ⁶CHU de Bordeaux, Bordeaux, France, ⁷Rheumatology Section, Department of Medicine, University of Verona, Italy, Verona, Italy, ⁸Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel, ⁹Poitiers's Universatory Hospital, Department of Internal Medicine, Poitiers, France, Mignaloux-Beauvoir, France, ¹⁰University College London, London, United Kingdom, ¹¹Università Politecnica delle Marche, Ancona, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Sorlandet sykehus, Kristiansand, Norway, ¹⁴Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, Oslo, Norway, ¹⁵University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ¹⁶University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, ¹⁷JLU Campus KK, Bad Nauheim, Germany, ¹⁸Hospital Universitari de la Santa Creu i Sant Pau, Vilafranca del Pened, Spain, ¹⁹Charité Hospital, Berlin, Germany, ²⁰University of Lille, LILLE, France, ²¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…
Abstract Number: 1941 • ACR Convergence 2022
Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents
Melissa Argraves¹, Melissa Lerman¹, Julie Chase² and Samuel Goldfarb³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Kentucky, Lexington, KY, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Idiopathic Pulmonary Hemosiderosis (IPH) is a rare, pediatric predominant condition causing episodic diffuse alveolar hemorrhage, which can be recurrent and life-threatening. Chronic steroid use…
Abstract Number: 1057 • ACR Convergence 2022
Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study
Ivette Casafont-Solé¹, Laura Calvo², Anne Riveros-Frutos³, Carlos De la Puente Bujidos⁴, Pau Alcubilla⁵, Lourdes Mateo¹ and Ivan Castellví⁶, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitario Ramon y Cajal, Madrid, Spain, ³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴Ramon y Cajal University Hospital, Madrid, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: Pulmonary arterial hypertension (PAH) leads to a progressive right heart failure and death.PAH is a leading cause of death in Systemic Sclerosis (SSc). To…
Abstract Number: 2160 • ACR Convergence 2022
The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients
Henriette Didriksen¹, Øyvind Molberg², Adi Mehta³, Suzana Jordan⁴, Håvard Fretheim³, Einar Gude³, Thor Ueland³, Cathrine Brunborg³, Vyacheslav Palchevskiy⁵, Torhild Garen³, Øyvind Midtvedt³, Arne Andreassen³, Fridtjof Lund-Johansen³, Oliver Distler⁴, John Belperio⁵ and Anna-Maria Hoffmann-Vold³, ¹Oslo University Hospital, Moss, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Chemokines appear to be important for the pathogenesis of autoimmune diseases. Humans may generate antibodies targeting chemokines leading to inhibition of signaling and driving…
Abstract Number: 1058 • ACR Convergence 2022
Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertension and Interstitial Lung Disease in Systemic Sclerosis
Jessica Fairley¹, Dylan Hansen², Laura Ross³, Susanna Proudman⁴, Jo Sahhar⁵, Gene-Siew Ngian⁶, Jenny Walker⁷, Lauren Host⁸, Kathleen Morrisroe², Diane Apostolopoulos⁹, Nava Ferdowsi², Michelle Wilson⁹, Maryam Tabesh², Wendy Stevens² and Mandana Nikpour¹⁰, ¹The University of Melbourne, Melbourne, Australia, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ⁴University of Adelaide, Medindie, Australia, ⁵Monash Health, Melbourne, Australia, ⁶Melbourne Health, Northcote, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Fiona Stanley Hospital, London, United Kingdom, ⁹Monash University, Melbourne, Australia, ¹⁰The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of systemic sclerosis (SSc) associated death. There is increasing interest in…
Abstract Number: 2172 • ACR Convergence 2022
Pulmonary Function in Patients Diagnosed of Early Systemic Sclerosis: 10 Years-Experience
Samuel Leal Rodriguez¹, Francisco Miguel Ortiz Sanjuan², José Ivorra Cortés³, Laura Mas Sanchez³, Pablo Muñoz Martinez⁴, Carmen Riesco Bárcena⁵, Anderson Huaylla Quispe⁶, Cristobal Pavez Perales³, Inés Cánovas Olmos³, Luis Gonzalez Puig⁷, Elena Grau García³, Isabel Martínez-Cordellat³, Carmen Nájera Herranz³, Rosa Negueroles Albuixech³, JOSE ELOY OLLER RODRIGUEZ⁸, Elvira Vicens Bernabeu², Alba Torrat Novés⁵, Daniel Ramos Castro³ and José andrés Román ivorra¹, ¹Hospital Universitari i Politécnic La Fe, València, Spain, ²Hospital Universitario de La Fe, València, ³Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ⁴Rheumatology Department. Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ⁶Medicina, València, Spain, ⁷Hospital La Fe, Torrente, Valencia, Spain, ⁸Hospital Universitario de La Fe, València, Spain
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc), often progressive and has a poor prognosis. A restrictive ventilatory defect could…
Abstract Number: L10 • ACR Convergence 2021
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
joshua solomon¹, Felix Woodhead², Sonye Danoff³, Shana Haynes-Harp⁴, Tanvi Naik⁵, Cathie Spino⁵, Shelley Hurwitz⁶, Rie Maurer⁶, Daniel Chambers⁷, Martin Kolb⁸, Hiliary Goldberg⁶ and Ivan Rosas⁴, ¹National Jewish Health, Denver, CO, ²University of Leicester, Leicester, United Kingdom, ³Johns Hopkins University, Baltimore, MD, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Brigham and Womens Hospital, Boston, MA, ⁷University of Queensland, Brisbane, Australia, ⁸McMaster University, Hamilton, ON, Canada
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…
Abstract Number: 1855 • ACR Convergence 2021
Up-regulation of TNFα Gene in Peripheral Blood Is Useful for Predicting the Development of Exercise-induced Pulmonary Hypertension, Which Is Early Stage of Pulmonary Vascular Disease Associated with Systemic Sclerosis
Yoshinobu Koyama¹, Yoshiharu Sato², Tatsuma Shoji², Soichiro Fuke¹, Takatsune Umayahara¹ and Moe Sakamoto¹, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: Pulmonary hypertension (PH) is prominent as a vascular involvement of systemic sclerosis (SSc), which remains a leading cause of death in spite of current…
Abstract Number: 0084 • ACR Convergence 2021
COVID-19 Pneumonia in Two Hospitals: Similar Outcomes Despite Differential Use of Tocilizumab
Leanna Wise¹, Lauren Mathias², Wendy Mack², Aarya Kafi³, Yash Kothari², Omkar Rao³ and William Stohl⁴, ¹LAC+USC/Keck Medicine of USC, Pasadena, CA, ²University of Southern California, Los Angeles, CA, ³University of California San Diego, San Diego, CA, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: A substantial number of patients with COVID-19 pneumonia develop a hyperinflammatory state. The anti-IL-6 receptor (IL-6R) mAb tocilizumab (TCZ) has been used in such…
Abstract Number: 0150 • ACR Convergence 2021
Clinical Characteristics and Quantitative CT Findings in Connective Tissue Disease-Associated Interstitial Lung Disease
Sirus Jesudasen¹, Badar Patel², Kristin D'Silva¹, Pietro Nardelli², Ruben San José Estépar², George Washko², Raúl San José Estépar², Farbod Rahaghi² and Sydney Montesi¹, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Precapillary Pulmonary Hypertension (PPH) is a known complication of connective tissue disease-associated interstitial lung disease (CTD-ILD) but at present requires right heart catheterization (RHC)…
Abstract Number: 0152 • ACR Convergence 2021
Deep Learning-Derived Chest Radiograph Scores in COVID-19 in Rheumatic Disease Patients versus General Population Comparators
Naomi Patel¹, Kristin D'Silva¹, Matthew Li¹, Tiffany Hsu², Michael Di Iorio³, Xiaoqing Fu¹, Claire Cook⁴, Lauren Prisco⁵, Lily Martin⁶, Kathleen Vanni⁶, Alessandra Zaccardelli⁶, Yuqing Zhang⁷, Jayashree Kalpathy-Cramer¹, Jeffrey Sparks⁶ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Quincy, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with rheumatic diseases and COVID-19 may have higher risk of mechanical ventilation than those without rheumatic diseases. We compared COVID-19 lung disease between…
Abstract Number: 0288 • ACR Convergence 2021
Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies
Gregory McDermott¹, Ritu Gill², Staci Gagne³, Suzanne Byrne³, Weixing Huang³, Lauren Prisco⁴, Alessandra Zaccardelli³, Lily Martin³, Nancy Shadick⁵, Paul Dellaripa³, Tracy Doyle⁶ and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Pound Ridge, MA, ⁵Brigham & Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Bronchiectasis is a known extra-articular manifestation of rheumatoid arthritis (RA) characterized by bronchial damage and excessive mucus production that predispose patients to risk of…
Abstract Number: 0290 • ACR Convergence 2021
Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
Didem Sahin Eroglu¹, Anil Colaklar², Serdar Baysal³, Murat Torgutalp¹, Asaf Baygul⁴, Serdar Sezer¹, Emine Aydemir Guloksuz¹, Mehmet Yuksel¹, Mucteba Yayla¹, Emine Uslu yurteri⁵, Caglar Uzun², Ozlem Ozdemir kumbasar⁴, Murat Turgay¹, Kinikli Gulay¹ and Askin Ates¹, ¹Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Ankara University Faculty of Medicine, Department of Radiology, Ankara, Turkey, ³Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴Ankara University Faculty of Medicine, Department of Pulmonology, Ankara, Turkey, ⁵Hatay Training and Research Hospital, Hatay, Turkey
Background/Purpose: Rheumatoid arthritis-related lung disease (RA-LD) is a common manifestation of rheumatoid arthritis (RA) and associated with excess mortality. Many studies to date were focused…
Abstract Number: 0291 • ACR Convergence 2021
IgA Anti-Cyclic Citrullinated Peptide Antibodies in Bronchoalveolar Lavage Fluid from Patients with Idiopathic Pulmonary Fibrosis Are Associated with Reduced Mortality
Scott Matson¹, Candace Cephers², Timothy Wilson³, Valerie Minarchick³, Kevin Brown⁴, Joshua Solomon⁴ and Kristen Demoruelle⁵, ¹University of Kansas, Kansas City, MO, ²St Joseph Hospital, Internal Medicine, Denver, CO, ³University of Colorado, Denver, CO, ⁴National Jewish Health, Denver, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Idiopathic pulmonary fibrosis (IPF) is a form of interstitial lung disease (ILD) that shares many clinical features with rheumatoid arthritis (RA) associated ILD. Our…
Abstract Number: 0497 • ACR Convergence 2021
Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
Victor Tapson¹, Steven Nathan², Reda Girgis³, James Runo⁴, Remzi Bag⁵, Arunabh Talwar⁶, Peter Smith⁷, Lisa Edwards⁷, Christine Park⁷ and Aaron Waxman⁸, ¹Cedars-Sinai, Los Angeles, CA, ²Inova Fairfax, Falls Church, VA, ³Michigan State University, Lansing, MI, ⁴University of Wisconsin, Madison, WI, ⁵University of Chicago, Chicago, IL, ⁶Hofstra Northwell School of Medicine, Hempstead, NY, ⁷United Therapeutics Corporation, Durham, NC, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: INCREASE was a 16-week trial evaluating the safety and efficacy of inhaled treprostinil (iTRE) in patients with pulmonary hypertension associated with interstitial lung disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].